Contact
searchSearch
HMP Global

Myeloproliferative Neoplasms

News
TKI-Treated CML Survivors Face Long-Term Health and Functional Challenges
08/24/2026
Grace Taylor, MS, MA
Long-term tyrosine kinase inhibitors (TKI) therapy has transformed chronic myeloid leukemia (CML) survival, but new findings suggest survivors may continue to experience substantial challenges with overall health, physical function, and...
Long-term tyrosine kinase inhibitors (TKI) therapy has transformed chronic myeloid leukemia (CML) survival, but new findings suggest survivors may continue to experience substantial challenges with overall health, physical function, and...
Long-term tyrosine kinase...
08/24/2026
First Report Managed Care
News
Recent CML Advances Reshape Frontline Treatment and TKI Sequencing
08/19/2026
Hannah Musick
Recent advances in chronic myeloid leukemia are expanding treatment options and supporting a more individualized approach that balances molecular response, toxicity, treatment-free remission goals, comorbidities, and cost.
Recent advances in chronic myeloid leukemia are expanding treatment options and supporting a more individualized approach that balances molecular response, toxicity, treatment-free remission goals, comorbidities, and cost.
Recent advances in chronic...
08/19/2026
First Report Managed Care
News
Later-Generation CML Therapies May Have Limited Effect on Patient Out-of-Pocket Costs
08/12/2026
Hannah Musick
A new economic analysis suggests that insured patients with chronic myeloid leukemia (CML) may face similar annual out-of-pocket costs across tyrosine kinase inhibitor options, despite substantially higher treatment costs for many...
A new economic analysis suggests that insured patients with chronic myeloid leukemia (CML) may face similar annual out-of-pocket costs across tyrosine kinase inhibitor options, despite substantially higher treatment costs for many...
A new economic analysis suggests...
08/12/2026
First Report Managed Care
News
TKI Dose De-Escalation Preserves Treatment-Free Remission in CML, Study Finds
07/20/2026
Grace Taylor, MS, MA
A study found that tyrosine kinase inhibitor (TKI) dose de-escalation preserved treatment-free remission while reducing adverse events in adults with chronic myeloid leukemia (CML).
A study found that tyrosine kinase inhibitor (TKI) dose de-escalation preserved treatment-free remission while reducing adverse events in adults with chronic myeloid leukemia (CML).
A study found that tyrosine...
07/20/2026
First Report Managed Care
News
Cavhanza Approved by the FDA to Treat Adults With Ph+ CML
07/20/2026
Rebecca Amrick
Cavhanza (nilotinib) has been approved by the US Food and Drug Administration (FDA) to treat adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), increasing treatment options for CML and possibly improving patient...
Cavhanza (nilotinib) has been approved by the US Food and Drug Administration (FDA) to treat adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), increasing treatment options for CML and possibly improving patient...
Cavhanza (nilotinib) has been...
07/20/2026
First Report Managed Care
News
Review Finds Low Bleeding Risk With Tyrosine Kinase Inhibitor–Anticoagulant Combinations in CML
07/16/2026
Hannah Musick
A systematic review found that combining tyrosine kinase inhibitors with anticoagulants was generally associated with a low incidence of bleeding and thrombotic events in chronic myeloid leukemia, although patients with renal impairment,...
A systematic review found that combining tyrosine kinase inhibitors with anticoagulants was generally associated with a low incidence of bleeding and thrombotic events in chronic myeloid leukemia, although patients with renal impairment,...
A systematic review found that...
07/16/2026
First Report Managed Care
News
TKI Discontinuation Supports Long-Term Treatment-Free Remission in Chronic-Phase CML
07/08/2026
Grace Taylor, MS, MA
A meta-analysis of 16 studies found that approximately half of patients with chronic-phase chronic myeloid leukemia (CML) remained in treatment-free remission for up to 36 months after discontinuing tyrosine kinase inhibitor (TKI) therapy,...
A meta-analysis of 16 studies found that approximately half of patients with chronic-phase chronic myeloid leukemia (CML) remained in treatment-free remission for up to 36 months after discontinuing tyrosine kinase inhibitor (TKI) therapy,...
A meta-analysis of 16 studies...
07/08/2026
First Report Managed Care
News
Food Restrictions May Affect Adherence in Chronic Myeloid Leukemia
06/18/2026
Hannah Musick
Food restrictions associated with certain chronic myeloid leukemia therapies were linked to greater treatment burden, missed doses, and adherence challenges, with more than half of surveyed patients expressing interest in a treatment option...
Food restrictions associated with certain chronic myeloid leukemia therapies were linked to greater treatment burden, missed doses, and adherence challenges, with more than half of surveyed patients expressing interest in a treatment option...
Food restrictions associated...
06/18/2026
First Report Managed Care
News
Food-Restricted TKIs Associated With Adherence Challenges in CML
06/08/2026
Grace Taylor, MS, MA
A US survey of patients with chronic myeloid leukemia (CML) found that food restrictions associated with certain tyrosine kinase inhibitors (TKIs) may complicate daily routines, reduce treatment adherence, and increase interest in more...
A US survey of patients with chronic myeloid leukemia (CML) found that food restrictions associated with certain tyrosine kinase inhibitors (TKIs) may complicate daily routines, reduce treatment adherence, and increase interest in more...
A US survey of patients with...
06/08/2026
First Report Managed Care
News
Asciminib Shows Durable Frontline Benefit in Newly Diagnosed CML
05/20/2026
Hannah Musick
At 96 weeks, asciminib demonstrated higher major molecular response rates and fewer treatment discontinuations due to adverse events compared with imatinib and second-generation tyrosine kinase inhibitors in newly diagnosed chronic myeloid...
At 96 weeks, asciminib demonstrated higher major molecular response rates and fewer treatment discontinuations due to adverse events compared with imatinib and second-generation tyrosine kinase inhibitors in newly diagnosed chronic myeloid...
At 96 weeks, asciminib...
05/20/2026
First Report Managed Care
Industry Insights
News
First Report Managed Care

Current Issue

June 2026
Volume 23
Issue 2
Current Issue
Issue Archive

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use